Trade Abbott Laboratories - ABT CFD
Add to favourite- Summary
- Historical Data
Spread | 0.15 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024901% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002679% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 116.98 |
Open | 117 |
1-Year Change | 20.82% |
Day's Range | 116.06 - 117 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 21, 2024 | 116.98 | -0.74 | -0.63% | 117.72 | 118.67 | 116.55 |
Oct 18, 2024 | 119.34 | 2.12 | 1.81% | 117.22 | 119.78 | 117.21 |
Oct 17, 2024 | 117.82 | -0.24 | -0.20% | 118.06 | 118.66 | 117.12 |
Oct 16, 2024 | 117.74 | 1.23 | 1.06% | 116.51 | 119.43 | 116.50 |
Oct 15, 2024 | 115.97 | -0.36 | -0.31% | 116.33 | 118.29 | 115.39 |
Oct 14, 2024 | 117.17 | 1.20 | 1.03% | 115.97 | 117.52 | 115.70 |
Oct 11, 2024 | 116.02 | 0.30 | 0.26% | 115.72 | 117.20 | 115.41 |
Oct 10, 2024 | 115.54 | -0.41 | -0.35% | 115.95 | 116.78 | 115.40 |
Oct 9, 2024 | 115.88 | 1.25 | 1.09% | 114.63 | 116.21 | 114.20 |
Oct 8, 2024 | 114.56 | 1.20 | 1.06% | 113.36 | 115.18 | 113.36 |
Oct 7, 2024 | 113.28 | 1.19 | 1.06% | 112.09 | 113.53 | 111.75 |
Oct 4, 2024 | 112.56 | 0.21 | 0.19% | 112.35 | 112.70 | 111.61 |
Oct 3, 2024 | 112.15 | -0.26 | -0.23% | 112.41 | 113.44 | 111.70 |
Oct 2, 2024 | 113.57 | 1.13 | 1.00% | 112.44 | 113.72 | 111.97 |
Oct 1, 2024 | 113.51 | 0.03 | 0.03% | 113.48 | 114.08 | 112.74 |
Sep 30, 2024 | 113.94 | 1.71 | 1.52% | 112.23 | 114.03 | 112.06 |
Sep 27, 2024 | 112.35 | -0.48 | -0.43% | 112.83 | 113.30 | 112.24 |
Sep 26, 2024 | 112.64 | 0.63 | 0.56% | 112.01 | 112.87 | 112.01 |
Sep 25, 2024 | 112.47 | -0.49 | -0.43% | 112.96 | 114.00 | 111.80 |
Sep 24, 2024 | 113.33 | -0.53 | -0.47% | 113.86 | 114.35 | 113.11 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Abbott Company profile
What is Abbott Laboratories?
Abbott Laboratories is a US healthcare company that employs around 99,000 people and delivers its services in over 150 countries worldwide. Abbott produces and distributes a range of products under such popular brands as PediaSure, Glucerna, Similac, Absorb and others. Its mission statement is: “To improve lives by providing cost-effective health care products and services.”
The company focuses on the following healthcare segments: Nutrition, Vascular Care, Diabetes Care, Vision, Pharmaceuticals and Diagnostics. It advocates for innovation in medicine and works to improve vision correction, take heart health treatments to the next level and introduce innovative methods of diabetes management.
Abbott has also pioneered new ways to screen, diagnose and monitor a wide range of health conditions with greater speed and accuracy. In pharmaceuticals, the company has revolutionised packaging and delivery to meet regional needs and offer access to medicines in areas that once lacked them.
Who are the key people at Abbott Laboratories?
Miles D. White is Chairman and Chief Executive Officer of Abbott. He has held both roles since 1999, and first joined the company back in 1984. Another key figure at Abbott Laboratories is Brian Blaser, Executive Vice President, Diagnostics Products. He leads Abbott's diagnostics, molecular and point-of-care businesses. Robert Ford is Executive Vice President, Medical Devices.
What is the modern history of Abbott Laboratories?
Abbott was incorporated in 1894, and its initial public offering took place in 1929. Among a number of landmark developments in the second half of the 20th century was the acquisition of M&R Dietetics in 1964, which made the company a leader in nutrition. Abbott’s modern diagnostics business took off in the early 1970s, and in 1985 the FDA approved the firm’s test to identify HIV in blood. In 1998 Abbott introduced Glucerna – a range of snack bars and shakes for diabetics. The first decade of the 21st century saw FDA approval of antibody drug Humira, which became the world’s leading pharmaceutical product.
What are the latest developments at Abbott Laboratories?
In January 2017 Abbott completed the acquisition of St Jude Medical – a development which put the company in a leading position in the medical devices sector. Abbott now holds the No.1 or No.2 positions in nearly every segment of the $30 billion cardiovascular market. In 2017 Abbott also recorded 40 per cent growth in its neuromodulation business, attaining the No.1 spot in spinal cord neurostimulation.
In February 2018, Abbott announced a licensing deal with mid-tech firm Surmodics Inc that could be worth up to $92 million. Under the agreement, Surmodics will exclusively license its SurVeil drug-coated balloon device to Abbott. Surmodics is testing it as a treatment for peripheral artery disease.
Since the start of 2015, the Abbott share price has ranged from a low of around $37 in February 2016 to over $60 in January 2018. The company’s market capitalisation on 2 March 2018 was $103.5 billion. Our ABT chart tracks Abbott’s recent share price movements.
Where does Abbott Laboratories operate?
Abbott is headquartered in Chicago, Illinois. It has a truly global presence, with operations across the Americas, Europe and Asia Pacific – including China, India, Japan, Australia and New Zealand.
Where is Abbott Laboratories traded?
Abbott Laboratories is listed on the New York Stock Exchange. As of 2017, the shares were mainly held by institutional investors such as BlackRock, State Street Corporation and The Vanguard Group. Check out Capital.com for the latest ABT chart.
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
100 Abbott Park Rd
ABBOTT PARK
ILLINOIS 60064-3500
US
News
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024Gold markets to trade
Last week, we explored the basic fundamental and technical approaches to gold trading. Having covered the key price drivers of this critical asset and how you might use data to trade it, you’re ready to assess the conditions for entry. But there are a range of markets that can effectively give you exposure to gold.
08:00, 21 October 2024US earnings seasons off to a solid start as focus shifts to tech giants
The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.
14:31, 17 October 2024ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
12:41, 16 October 2024Australian labour force data forecast to reveal stable jobs market
Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.
07:41, 15 October 2024Applying fundamental and technical strategies to Gold Trading
Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.
08:00, 14 October 2024S&P 500 expected to deliver modest earnings growth in Q3
Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.
12:40, 11 October 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com